ClinicalTrials.gg
RecruitingNCT06291805Updated Aug 15, 2025

Phenotyping and Characterization of wtATTR-CM (TRACE 1)

An observational study in Transthyretin Amyloidosis, Transthyretin Amyloid Cardiomyopathy and Wild-Type Transthyretin-Related (ATTR)Amyloidosis, sponsored by Steen Hvitfeldt Poulsen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Steen Hvitfeldt Poulsen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Denmark — 6 open to participants now, 7 under way, 4 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · Denmark.

Started
2024
with 1 other
Observational
4 of 11
3 open now
Registered
8th of 11
by date
Lead sponsor
2 of 11
Steen Hvitfeldt Poulsen

Among the 11 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Denmark, this one is one of 2 that started in 2024, is one of 4 observational ones, and was the 8th registered.

Amyloidosis, Hereditary, Transthyretin-Related

82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.

Browse Amyloidosis, Hereditary, Transthyretin-Related studies →

Open to participants now

6 of the 11 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Denmark are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Denmark, or all of them as a file.
02

Study summary

Descriptive cross-sectional study on 100 consecutive ATTRwt-CM patients reflecting all NAC stages aiming primarily to investigate ATTRwt-CM patient's quality of life (QoL) measures and their relation to ATTRwt-CM severity. Secondarily aiming to investigate the possibility to measure misTTR and fragTTR in plasma and urine and to detect fragTTR in endomyocardial biopsies from ATTRwt-CM patients. To investigate whether misTTR and fragTTR levels are correlated with ATTRwt-CM severity.

Read the detailed description

Hypothesis:

  1. We hypothesize that more severe wild-type amyloidosis cardiomyopathy (ATTRwt-CM) according to clinical, biochemical, and diagnostic imaging parameters are correlated with worse quality of life (QoL) for patients.
  2. We expect misfolded (misTTR) and/or fragmented transthyretin (fragTTR) to be measurable in plasma and/or urine and fragTTR to be detectable in endomyocardial biopsies from patients with ATTRwt-CM. We expect the values of misTTR and fragTTR to be correlated with the severity of ATTRwt-CM according to clinical, biochemical, and diagnostic imaging parameters. We expect the level of fragTTR from endomyocardial biopsies to be correlated with plasma levels of fragTTR.

Method:

ATTRwt-CM patients: Prospective inclusion of 100 consecutive ATTRwt-CM patients reflecting all NAC stages (40 patients from NAC disease stage 1, 40 patients from NAC disease stage II and 20 patients from NAC disease stage III). Patients will be recruited from the out-patient amyloidosis clinic at Aarhus University hospital. Patients will be thoroughly clinically assessed.

Control patients:

A control cohort of 20 age- and gender-matched heart-healthy patients will be included for comparison of total/mis-/fragTTR values.

The investigating into QoL, bio markers and the analyses on cardiac MR imaging markers will hopefully provide us with tools to evaluate and monitor disease progression and response to treatment.

03

Conditions studied

  • Transthyretin Amyloidosis
  • Transthyretin Amyloid Cardiomyopathy
  • Wild-Type Transthyretin-Related (ATTR)Amyloidosis
  • Quality of Life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Including variating severity of wtATTR-CM by including 40 patients with NAC stage 1, 40 patients with NAC stage 2, and 20 patients with NAC stage 3. Furthermore, including a healthy control group in order to examine normal values of mis- and frag-TTR

Eligibility criteria

Group 1: wtATTR-CM patients

Inclusion Criteria:

  • Patients > 18 years diagnosed with ATTRwt-CM by:
  • endomyocardial
  • DPD scintigraphy with Perugini grade 2-3 where variant amyloidosis is ruled out due to genetic testing.
  • Informed oral and written consent

Exclusion Criteria:

  • AL amyloidosis (light-chain amyloidosis).
  • Myelomatosis
  • Waldenström macroglobulinemia

Group 2: Control group

Inclusion Criteria:

  • Patients > 18 years
  • Informed oral and written consent

Exclusion Criteria:

  • Known cardiovascular disease including ischemic heart disease, heart failure, atrial fibrillation, presence of a pacemaker, or malignant hypertension. Well-controlled hypertension is acceptable.
  • Suspicion of cardiac amyloidosis assessed through clinical history, physical examination, , and echocardiography focusing on "red flags":
  • Echocardiography with:
  • Myocardial hypertrophy (septum >11 mm)
  • Apical sparing in LV-GLS
  • Infiltrative changes in the right ventricle free wall, thickened atrioventricular valves, or thickened atrial septum
  • Symptoms of polyneuropathy
  • Low voltage on ECG or discrepancy between left ventricular thickness and ECG amplitude indicative of low voltage
  • Atrioventricular block (AV block)
  • Bilateral carpal tunnel syndrome
  • Surgery for spinal stenosis
  • Elevated troponin I or NT-pro-BNP
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
120 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • wtATTR-CM patients (n = 100)

    Clinical history, physical examination, ECG, advanced echocardiography, blood and urine samples, cardiac magnetic resonance imaging (CMRI), and QoL questionaires (KCCQ, EQ-5Q-5L and ATTR-QoL)). Subgroup with these patient (n = 10): A endomyocardial biopsy.

  • Control (n = 20)

    Blood and urine samples. To rule out cardiac disease: clinical history, physical examination, ECG and advanced echocardiography.

06

What researchers measure

Primary outcomes

  1. Investigation of cardiac amyloidosis severity in patients with Wild-type Transthyretin Amyloidosis Cardiomyopathy.

    Amyloid severity will be addressed using primarily NAC-stages and NYHA-class. Furthermore, we will use NT-pro-BNP, findings on echo (stroke volume, ejectionfraction and global longitudional strain) and finding on CMRI (LV mass, T1 myocardial values and extracellular volume).

    Time frame: Through study completion, 2 years.

  2. Investigation of the relations between cardiac amyloid severity and patient quality of life in patients with Wild-type Transthyretin Amyloidosis Cardiomyopathy.

    Quality of life will be addressed using KCCQ summary score, EQ-5D Utility score and VAS ranging score and ATTR-QOL total score.

    Time frame: Through study completion, 2 years.

  3. Assessment of transthyretin and pathogenic fragments and relation to cardiac amyloid severity in patients with Wild-type Transthyretin Amyloidosis Cardiomyopathy

    Transthyretin (TTR) will be measured as follows: total TTR, misfolded TTR and fragmented TTR in plasma and misfolded TTR and fragmented TTR in urine.

    Time frame: Through study completion, 2 years.

Secondary outcomes

  1. Validation of a new amyloid specific questionnaire (ATTR-QoL) in comparison with Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Comparing ATTR-QOL total score to KCCQ summary score and EQ-5D Utility score and VAS ranging score.

    Time frame: Through study completion, 2 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Dec 2025, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2024
First posted
Mar 4, 2024
StartActual
Feb 20, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06291805
Lead sponsor
Steen Hvitfeldt Poulsen
Collaborators
Novo Nordisk A/S
Responsible party
Steen Hvitfeldt Poulsen (Professor, DMSc., Aarhus University Hospital Skejby) — Sponsor-investigator
First posted
Mar 4, 2024
Start date
Feb 20, 2024
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Aug 15, 2025

Study contacts

Sie Kronborg Fensman, MD
Contact
siefensman@gmail.com
+45 30 48 88 85

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion